- •Foreword
- •Preface
- •Contents
- •1.1 Introduction
- •1.2 Method
- •1.2.1 Databases
- •1.2.2 Dates
- •1.2.3 Keywords
- •1.2.4 Criteria for Inclusion
- •1.2.5 Criteria for Exclusion
- •1.2.6 Selection of Papers
- •1.3 Results
- •1.3.1 Subspecialty
- •1.3.2 Type of Telemedicine
- •1.3.3 Study Design
- •1.3.4 Final Conclusions of Papers
- •1.4 Discussion
- •References
- •2.1 Introduction
- •2.2 The Need for Diabetic Retinopathy Screening Programs
- •2.4 Guidelines for Referring Patients
- •2.7 Program Models for Diabetic Retinopathy Screening
- •2.9 Program Personnel and Operations
- •2.9.1 Primary Care Providers
- •2.9.2 Photographers
- •2.9.3 Clinical Consultants
- •2.9.4 Administrators
- •2.9.5 A Note to CEOs, Operations Directors, and Clinic Managers
- •2.10 Policies and Procedures
- •2.10.1 Sample Protocol 1
- •2.10.1.1 Diabetic Retinopathy Screening Services
- •Policy
- •Background
- •Procedure
- •2.10.2 Sample Protocol 2
- •2.10.2.1 Pupil Dilation Before Diabetic Retinopathy Photography
- •Policy
- •Background
- •Procedure
- •2.10.3 Sample Protocol 3
- •2.10.3.1 Diabetic Retinopathy Photography Review
- •Policy
- •Background
- •Procedure
- •2.11 Technical Requirements
- •2.11.1 Connectivity
- •2.11.2 Resolution
- •2.11.3 Color
- •2.11.4 Stereopsis
- •2.11.5 Compression
- •2.11.6 Enhancement
- •2.11.7 Pupil Dilation
- •2.11.8 Early California Telemedicine Initiatives Diabetic Retinopathy Screening
- •2.11.9 The American Indian Diabetes Teleophthalmology Grant Program
- •2.11.10 Central Valley EyePACS Diabetic Retinopathy Screening Project
- •2.12.1 Diabetic Retinopathy
- •2.12.1.1 ADA Guidelines Terms
- •2.12.1.2 Vitrectomy
- •References
- •3: Stereopsis and Teleophthalmology
- •3.1 Introduction
- •3.2 History of Stereopsis and Stereopsis in Ophthalmology
- •3.3 Technology and Photography
- •3.3.3 Imaging Fields
- •3.3.4 Image Viewing Techniques
- •3.3.5 Image Compression
- •3.4 Stereoscopic Teleophthalmology Systems
- •3.4.1 University of Alberta
- •3.4.4 Joslin Vision Network
- •3.5 Conclusion
- •References
- •4.1 Introduction
- •4.2 Methods
- •4.2.1 Main Outcome Measures
- •4.3 Results
- •4.3.1 Retinal Video Recording Versus Retinal Still Photography
- •4.3.2 Video Compression Analysis
- •4.4 Discussion
- •References
- •5.1 Introduction
- •5.1.1 Automated, Remote Image Analysis of Retinal Diseases
- •5.1.2 Telehealth
- •5.2 Design Requirements
- •5.2.1 Telehealth Network Architecture
- •5.2.2 Work Flow
- •5.2.3 Performance Evaluation of the Network
- •5.3 Automated Image Analysis Overview
- •5.3.1 Quality Assessment Module
- •5.3.2 Vascular Tree Segmentation
- •5.3.3 Quality Evaluation
- •5.4 Anatomic Structure Segmentation
- •5.4.1 Optic Nerve Detection
- •5.4.2 Macula
- •5.4.3 Lesion Segmentation
- •5.4.4 Lesion Population Description
- •5.4.5 Image Query
- •5.5 Summary
- •References
- •6.1 Introduction
- •6.3 Optical Coherence Tomography to Detect Leakage
- •References
- •7.1 Introduction
- •7.2 Patients and Methods
- •7.2.1 Participants
- •7.2.2 Methods
- •7.2.3 Statistics
- •7.3 Results
- •7.3.1 Reliability of Image Evaluation
- •7.3.2 Prevalence of Glaucomatous Optic Nerve Atrophy
- •7.4 Discussion
- •7.5 Perspectives
- •References
- •8.1 Introduction
- •8.1.2 Homology Between Retinal and Systemic Microvasculature
- •8.1.3 Need for More Precise CVD Risk Prediction
- •8.2.1 Retinal Microvascular Signs
- •8.2.2 Retinal Vessel Biometry
- •8.2.3 Newer Retinal Imaging for Morphologic Features of Retinal Vasculature
- •8.3 Associations of Retinal Imaging and CVD Risk
- •8.3.1.1 Risk of Pre-clinical CVD
- •8.3.1.2 Risk of Stroke
- •8.3.1.3 Risk of Coronary Heart Disease
- •8.3.2.1 Risk of Hypertension
- •8.3.2.2 Risk of Stroke
- •8.3.2.3 Risk of Coronary Heart Disease
- •8.3.2.4 Risk of Peripheral Artery Disease
- •8.3.3 Newer Morphologic Features of Retinal Vasculature
- •8.4 Retinal Imaging and Its Potential as a Tool for CVD Risk Prediction
- •References
- •9.1 Alzheimer’s Disease
- •9.2 Treatments
- •9.3 Diagnosis
- •9.6 Conclusions
- •References
- •10.1 Introduction
- •10.1.1 Stroke
- •10.1.2 Heart Disease
- •10.1.3 Arteriovenous Ratio
- •10.2 Purpose
- •10.3 Method
- •10.3.1 Medical Approach
- •10.3.2 Technical Approach
- •10.3.3 Output of Medical Data
- •10.4 Patients
- •10.5 Results
- •10.5.1 Medical History
- •10.5.2 Telemedical Evaluation of Retinal Vessels
- •10.5.2.1 Prevalence of Retinal Microangiopathy
- •10.5.2.2 Arteriovenous Ratio
- •10.5.2.3 PROCAM-Index
- •10.6 Discussion and Perceptive
- •10.6.1 Estimation of “Stroke Risk” Estimated by the Stage of Retinal Microangiopathy
- •References
- •11.1 Introduction
- •11.2 System Requirements
- •11.3 Fundus Camera
- •11.4 Imaging Procedure
- •11.4.1 Reading Center Procedure
- •11.5 Detection of Macular Edema
- •11.6 Implementation
- •11.7 Unreadable Images
- •11.7.1 Impact on Overall Diabetic Retinopathy Assessment Rates
- •11.7.2 Compliance with Recommendations
- •11.7.3 Challenges
- •11.7.4 Summary
- •References
- •12.1 Screening
- •12.2 Background
- •12.3 Historical Perspective in England
- •12.4 Methodology
- •12.4.1 The Aim of the Programme
- •12.5 Systematic DR Screening
- •12.6 Cameras for Use in the English Screening Programme
- •12.7 Software for Use in the English Screening Programme
- •12.9 Implementation in England
- •12.11 Quality Assurance
- •12.12 The Development of External Quality Assurance in the English Screening Programme
- •12.13 Information Technology (IT) Developments for the English Screening Programme
- •12.14 Dataset Development
- •12.15 The Development of External Quality Assurance Test Set for the English Screening Programme
- •12.16 Failsafe
- •12.17 The Epidemic of Diabetes
- •References
- •13.1 Introduction
- •13.2 Burden of Diabetes and Diabetic Retinopathy in India
- •13.3 Diabetic Retinopathy Screening Models
- •13.4 Need for Telescreening
- •13.5 Guidelines for Telescreening
- •13.6 ATA Categories of DR Telescreening Validation
- •13.7 Yield of Diabetic Retinopathy in a Telescreening Model
- •13.8 How Are Images Transferred
- •13.10 How Many Fields Are Enough for Diabetic Retinopathy Screening
- •13.11 Is Mydriasis Needed While Using Nonmydriatic Camera?
- •13.12 Validation Studies on Telescreening
- •13.12.1 Accuracy of Telescreening
- •13.12.2 Patient Satisfaction in Telescreening
- •13.12.3 Cost Effectivity
- •13.12.4 Telescreening for Diabetic Retinopathy: Our Experience
- •13.13 Future of Diabetic Retinopathy Screening
- •References
- •14.1 Introduction
- •14.2 Methods
- •14.3 Discussion
- •14.4 Conclusion
- •References
- •15.1 Introduction
- •15.1.1 Description of the EADRSI
- •15.5 State Support of Screening in the Safety Net
- •15.7 Screening Economics for Providers
- •15.8 Patient Sensitivity to Fees
- •15.9 Conclusion
- •References
- •16.1 Introduction
- •16.2 Setting Up the New Screening Model
- •16.2.1 Phase 1: Training
- •16.2.2 Phase 2: Evaluation of Agreement
- •16.2.3 Phase 3: Implementation of the Screening Model
- •16.3 Technologic Requirements
- •16.3.1 Data Management
- •16.3.2 Data Models
- •16.3.2.1 Data Scheme for Patient-Related Information
- •16.3.2.2 Data Scheme for Images
- •Fundus Camera VISUCAM Pro NM
- •PACS Server
- •ClearCanvas DICOM Visualizer
- •16.4 Results
- •16.4.1 Phase 2: Agreement Evaluation
- •16.4.2 Phase 3: Implementation of the Screening Model
- •16.5 Discussion
- •16.5.1 Evaluation of the Screening Model
- •16.5.2 Prevalence of DR
- •16.5.3 Quality Evaluation
- •16.6 Conclusion
- •References
- •17.1.3 Examination and Treatment
- •17.1.4 Limitations of Current Care
- •17.2 Telemedicine and ROP
- •17.2.2 Accuracy and Reliability of Telemedicine for ROP Diagnosis
- •17.2.3 Operational ROP Telemedicine Systems
- •17.2.4 Potential Barriers
- •17.3 Closing Remarks
- •17.3.1 Future Directions
- •References
- •18.1 Introduction
- •18.2 Neonatal Stress and Pain
- •18.3 ROP Screening Technique
- •18.4 Effect of Different Examination Techniques on Stress
- •18.5 Future of Retinal Imaging in Babies
- •References
- •19.1 Introduction
- •19.2 History of the Program
- •19.3 Telehealth Technologies
- •19.4 Impact of the Program
- •Selected References
- •Preamble
- •Introduction
- •Background
- •The Diabetic Retinopathy Study (DRS)
- •Mission
- •Vision
- •Goals
- •Guiding Principles
- •Ethics
- •Clinical Validation
- •Category 1
- •Category 2
- •Category 3
- •Category 4
- •Communication
- •Medical Care Supervision
- •Patient Care Coordinator
- •Image Acquisition
- •Image Review and Evaluation
- •Information Systems
- •Interoperability
- •Image Acquisition
- •Compression
- •Data Communication and Transmission
- •Computer Display
- •Archiving and Retrieval
- •Security
- •Reliability and Redundancy
- •Documentation
- •Image Analysis
- •Legal Requirements
- •Facility Accreditation
- •Privileging and Credentialing
- •Stark Act and Self-referrals
- •State Medical Practice Acts/Licensure
- •Tort Liability
- •Duty
- •Standards of Care
- •Consent
- •Quality Control
- •Operations
- •Customer Support
- •Originating Site
- •Transmission
- •Distant Site
- •Financial Factors
- •Reimbursement
- •Grants
- •Federal Programs
- •Other Financial Factors
- •Equipment Cost
- •Summary
- •Abbreviations
- •Appendices
- •Appendix A: Interoperability
- •Appendix B: DICOM Metadata
- •Appendix C: Computer-Aided Detection
- •Appendix D: Health Insurance Portability and Accountability Act (HIPAA)
- •Appendix F: Quality Control
- •Appendix H: Customer Support
- •Level 1
- •Level 2
- •Level 3
- •Appendix I: Reimbursement
- •Medicare
- •Medicaid
- •Commercial Insurance Carrier Reimbursement
- •Other Financial Factors
- •Disease Prevention
- •Resource Utilization
- •American Telemedicine Association’s Telehealth Practice Recommendations for Diabetic Retinopathy
- •Conclusion
- •References
- •Contributors
- •Second Edition
- •First Edition
- •Index
7 Tele-glaucoma: Experiences and Perspectives |
69 |
|
|
Fig. 7.1 Screenshot of the diagnosis program MedStage which was used for telemedical evaluation
optic nerve head was assessed within the image evaluation process to detect macropapillas. The criteria deÞned by Jonas [12] were used for diagnosis of glaucomatous optic nerve atrophy, which was based on the following signs: (1) rim inferior or rim superior was smaller than temporal rim,
(2) peripapillary hemorrhages, (3) localized nerve Þber layer defects, and (4) diffuse nerve Þber loss with glaucomatous cupping.
No visual Þeld test was performed. For the diagnosis of glaucomatous optic nerve atrophy, only the morphological pathology of the optic nerve head was examined. All images were stored electronically.
7.2.3Statistics
variables. The signiÞcance level for statistical tests was set to 0.05. The exact logistic regression models were computed with the statistical software package SAS 8.2, and the graphics were created with the freely available statistical programming environment R [13].
The correlation coefÞcient of reliability was determined by Cronbach alpha at the 95% conÞdence interval. The corresponding F-statistics were calculated as multivariate analysis from the Hotelling T2 test using SPSS software.
7.3Results
7.3.1Reliability of Image Evaluation
For statistical analysis, we compared several logistic regression models with different predictor
Two hundred and twelve monoscopic fundus images were randomly selected from the database mentioned above. Two ophthalmologists
70 |
|
|
|
|
|
G. Michelson et al. |
||
|
|
|
|
|
||||
Table 7.1 Prevalence of |
Age group |
Study population |
|
Glaucomatous optic nerve atrophy |
||||
glaucomatous optic nerve |
(years) |
Female |
Male |
Total |
Female (%) |
Male (%) |
Total (%) |
|
atrophy |
||||||||
45Ð49 |
1,140 |
1,894 |
3,034 |
0 (0.00) |
2 (0.11) |
2 (0.07) |
||
|
||||||||
|
50Ð54 |
1,235 |
1,765 |
3,000 |
1 (0.08) |
11 (0.62) |
12 (0.40) |
|
|
55Ð59 |
876 |
1,350 |
2,226 |
4 (0.46) |
6 (0.44) |
10 (0.45) |
|
|
60Ð64 |
571 |
771 |
1,342 |
4 (0.70) |
7 (0.91) |
11 (0.82) |
|
|
Total |
3,822 |
5,780 |
9,602 |
9 (0.24) |
26 (0.45) |
35 (0.36) |
|
assessed the images independently from each other two times according to the possible diagnoses: no glaucoma (grading 0Ð2), suspicious for glaucoma (grading 3Ð7), or deÞnite glaucoma (grading 8Ð10). The grading was based on subjective assessment and experience. If the difference between Þrst and second assessment differed less than two ranks from each other, the diagnosis was considered as conÞrmed. Alternatively, the diagnosis was classiÞed as not conÞrmed.
The intraobserver reliability was 0.884 and 0.840, respectively, for the two observers. The interobserver reliability of the Þrst cycle of evaluation was 0.740. Corresponding T2 for the intraobserver reliability was not signiÞcantly different (0.550, p = 0.459, and 0.033, p = 0.856, respectively), indicating that the mean values of the two cycles did not vary for each observer. The interobserver reliability, however, was (7.647, p = 0.006) with df1 = 1 and df2 = 211 each. This means that mean values of two cycles varied signiÞcantly between observers. Evaluation methods of images during all four assessment cycles did not increase the inner consistency in any noteworthy way (Cronbach alpha 0.870).
7.3.2Prevalence of Glaucomatous Optic Nerve Atrophy
We found 35 cases (0.36%) of glaucomatous optic nerve atrophy in the study population. Three cases have been previously diagnosed as glaucomatous. The proportion of glaucomatous optic nerve atrophy was smaller among women (9 cases: 0.24%) than among men (26 cases: 0.45%). The inßuence of age on the prevalence of glaucomatous optic nerve atrophy is illustrated in Table 7.1.
We found 2 cases (0.07%) of glaucomatous optic nerve atrophy in the age group 45Ð49 years, 12 cases (0.40%) in the group 50Ð54 years, 10 cases (0.45%) in the group 55Ð59 years, and 11 cases (0.82%) in the group 60Ð64 years (see Fig. 7.2).
To establish the age dependency of glaucomatous optic nerve atrophy, we Þtted a logistic regression model with age as the predictor variable and presence of glaucomatous optic nerve atrophy as the dependent variable. Because of the small case number, we computed the exact logistic regression [14] instead of the approximation, resulting in a highly signiÞcant model (p < 0.0001 for the estimated parameter). We examined dependency of glaucomatous optic nerve atrophy on gender by Þtting an exact logistic regression model using age group and gender as predictor variables. The resulting parameter estimates for gender and for the interaction of gender with age did not prove to be signiÞcantly different from zero (p = 0.14 and p = 0.20, respectively).
Two thousand two hundred and Þfty participants reported previous diagnosis of arterial hypertension. Among those were 13 participants with glaucomatous optic nerve atrophy. Four hundred and eight persons could not tell if they had arterial hypertension. Two hundred and ninety-four participants, including 20 glaucomatous optic nerve atrophy patients, reported previously raised IOP (148 women, 146 men). Two hundred and Þfty-four participants could not tell if their IOP was raised or not. Because these data were not measured but only reported and therefore open to doubt, we did not evaluate them statistically. One thousand four hundred and four persons reported to have a family history of glaucoma (see Table 7.3). Eight of these persons had glaucomatous optic nerve atrophy.
7 Tele-glaucoma: Experiences and Perspectives |
71 |
|
|
Fig. 7.2 Prevalence of glaucomatous optic nerve atrophy (own data).
The age groups <40, 40Ð44, and >64 are included for comparison with other studies
(see Table 7.2)
Table 7.2 Prevalence of open-angle glaucoma from the meta-analysis by the Eye Diseases Prevalence Research Group [16]
Table 7.3 Prevalence of glaucomatous optic nerve atrophy in subjects with and without family history of glaucoma (glaucoma in grandparents, parents, siblings, or children)
0.020
|
|
Female |
|
|
|
|
|
atrophy |
|
Male |
|
|
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
nerveoptic |
0.015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
glaucomatousof |
0.010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prevalence |
0.005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.000 |
40−44 |
45−49 |
50−54 |
55−59 |
60−64 |
>64 |
|
<40 |
||||||
|
|
|
Age group (years) |
|
|
||
|
Prevalence of OAG from |
Prevalence of glaucomatous optic |
||
Age group |
pooled data |
|
nerve atrophy (tele-glaucoma study) |
|
(years) |
Women (%) |
Men (%) |
Women (%) |
Men (%) |
40Ð49 |
0.83 |
0.36 |
0.00 |
0.13 |
50Ð54 |
0.89 |
0.61 |
0.08 |
0.62 |
55Ð59 |
1.02 |
0.85 |
0.46 |
0.44 |
60Ð64 |
1.23 |
1.18 |
0.70 |
0.91 |
65Ð69 |
1.58 |
1.64 |
1.58 |
0.26 |
70Ð74 |
2.16 |
2.27 |
1.35 |
3.57 |
75Ð79 |
3.12 |
3.14 |
2.27 |
8.33 |
>79 |
6.94 |
5.58 |
0.00 |
7.14 |
The numbers are generated from pooled data from the Baltimore Eye Survey, the Blue Mountains Eye Study, the Beaver Dam Study, the Rotterdam Study, and the Melbourne VIP, and the prevalence of glaucomatous optic nerve atrophy found in our study
|
Population with family history |
Population without family history |
||
Age group |
|
Glaucomatous optic |
|
Glaucomatous optic nerve |
(years) |
Total |
nerve atrophy (%) |
Total |
atrophy (%) |
45Ð49 |
465 |
0 (0.00) |
2,569 |
2 (0.08) |
50Ð54 |
448 |
4 (0.89) |
2,552 |
8 (0.31) |
55Ð59 |
294 |
1 (0.34) |
1,932 |
9 (0.47) |
60Ð64 |
197 |
3 (1.52) |
1,145 |
8 (0.70) |
Total |
1,404 |
8 (0.57) |
8,198 |
27 (0.33) |
